In a patient with an estimated glomerular filtration rate of 42 mL/min/1.73 m², can bisoprolol 10 mg and bilastine 20 mg be continued at their usual doses?

Dosing Recommendations for Bisoprolol and Bilastine with GFR 42 mL/min/1.73 m²

Bisoprolol 10 mg should be reduced to 5 mg daily, while bilastine 20 mg can be continued at the usual dose without adjustment.

Bisoprolol Dose Adjustment Required

Your patient's GFR of 42 mL/min/1.73 m² falls into the CKD G3b category (30-44 mL/min/1.73 m²), which requires dose modification for beta-blockers. The KDOQI guidelines explicitly recommend reducing beta-blocker doses by 50% in patients with GFR < 30 ml/min/1.73 m² 1. While your patient's GFR is slightly above this threshold at 42 mL/min/1.73 m², the current dose of 10 mg is already at the higher end of the therapeutic range.

Rationale for Dose Reduction:

• Bisoprolol pharmacokinetics are significantly altered in renal impairment: The FDA label states that in patients with creatinine clearance <40 mL/min, the plasma half-life increases approximately threefold compared to healthy subjects 2
• Initial dosing guidance: The FDA recommends starting at 2.5 mg daily in patients with hepatic impairment or renal dysfunction (creatinine clearance <40 mL/min), with cautious dose titration 2
• Your patient is at the threshold: With GFR 42 mL/min/1.73 m², this patient is borderline for the <40 mL/min category where drug accumulation becomes clinically significant

Practical Approach:

• Reduce bisoprolol from 10 mg to 5 mg once daily
• Monitor heart rate, blood pressure, and clinical response over 2-4 weeks
• Reassess renal function in 1-2 weeks after dose adjustment to ensure stability
• If further GFR decline occurs to <30 mL/min/1.73 m², reduce to 2.5 mg daily per guideline recommendations 1

Important caveat: Do not abruptly discontinue bisoprolol, as this can precipitate acute cardiac events, especially in patients with coronary artery disease 2. The dose reduction should be implemented as a single step-down.

Bilastine Requires No Dose Adjustment

Bilastine 20 mg daily can be safely continued without modification at this level of renal function.

Evidence Supporting Continued Standard Dosing:

The pivotal pharmacokinetic study specifically evaluated bilastine in patients with varying degrees of renal insufficiency 3. Key findings:

• Patients with moderate renal insufficiency (GFR 30-50 mL/min/1.73 m²) showed increased exposure (AUC increased from 737.4 ng·h/mL in healthy subjects to approximately 1200-1400 ng·h/mL in moderate impairment)
• Critical safety finding: Despite this increased exposure, bilastine remained well within safety margins, with no dose-related adverse events
• Conclusion from the study: "A 20-mg daily dose can be safely administered to subjects with different degrees of renal insufficiency without the need for dose adjustments" 3

Why No Adjustment is Needed:

• Bilastine is highly specific for H1 receptors with minimal off-target effects 4
• The drug has a wide therapeutic window
• Renal excretion is the main elimination route, but even with 2-3 fold increases in exposure in severe renal impairment, no safety concerns emerged 3
• Your patient's GFR of 42 mL/min/1.73 m² places them in the moderate renal insufficiency category where the study demonstrated safety without dose modification

Monitoring Considerations:

While no dose adjustment is required, remain vigilant for:

• Excessive antihistamine effects (though bilastine is non-sedating even at 80 mg daily 4)
• Any decline in renal function that might push GFR below 30 mL/min/1.73 m² (though even severe impairment didn't require adjustment in studies)

Summary Algorithm

For GFR 42 mL/min/1.73 m²:

1. Bisoprolol: Reduce from 10 mg to 5 mg daily (50% reduction approaching the GFR <30 threshold where guidelines mandate dose reduction)
2. Bilastine: Continue 20 mg daily unchanged (evidence-based safety data supports no adjustment)
3. Recheck renal function in 1-2 weeks post-bisoprolol adjustment
4. If GFR declines to <30 mL/min/1.73 m²: Further reduce bisoprolol to 2.5 mg daily; bilastine still requires no change

This approach prioritizes cardiovascular morbidity and mortality by maintaining beta-blocker therapy at an appropriate dose while avoiding drug accumulation, and safely continues effective antihistamine therapy without unnecessary restrictions.